These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models. Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333 [TBL] [Abstract][Full Text] [Related]
6. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504 [No Abstract] [Full Text] [Related]
7. Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era. Götz V; Mathé P; Agarwal P; Hornuss D; Pfau S; Panning M; Prager E; Voll RE; Engelhardt M; Frye BC; Bamberg F; Fuchs J; Müller M; Wagner D; Rieg S Infection; 2024 Jun; 52(3):923-933. PubMed ID: 38095753 [TBL] [Abstract][Full Text] [Related]
8. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study. Fountain-Jones NM; Vanhaeften R; Williamson J; Maskell J; Chua IJ; Charleston M; Cooley L Lancet Microbe; 2024 May; 5(5):e452-e458. PubMed ID: 38527471 [TBL] [Abstract][Full Text] [Related]
9. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225 [TBL] [Abstract][Full Text] [Related]
10. The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody. Maruyama S; Wada D; Kanayama S; Shimazu H; Miyano Y; Inoue A; Kashihara M; Okuda K; Saito F; Nakamori Y; Ishii K; Kuwagata Y BMC Infect Dis; 2024 Jul; 24(1):715. PubMed ID: 39039440 [TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study. Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665 [TBL] [Abstract][Full Text] [Related]
12. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK mBio; 2020 May; 11(3):. PubMed ID: 32444382 [TBL] [Abstract][Full Text] [Related]
13. Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection Gamage AM; Tan KS; Chan WOY; Lew ZZR; Liu J; Tan CW; Rajagopalan D; Lin QXX; Tan LM; Venkatesh PN; Ong YK; Thong M; Lin RTP; Prabhakar S; Wang Y; Wang LF mBio; 2022 Feb; 13(1):e0343621. PubMed ID: 35038898 [TBL] [Abstract][Full Text] [Related]
14. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection. Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921 [TBL] [Abstract][Full Text] [Related]
16. The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19. Penrice-Randal R; Bentley EG; Sharma P; Kirby A; Donovan-Banfield I; Kipar A; Mega DF; Bramwell C; Sharp J; Owen A; Hiscox JA; Stewart JP bioRxiv; 2024 Jun; ():. PubMed ID: 38464327 [TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795 [TBL] [Abstract][Full Text] [Related]
18. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial. Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502 [TBL] [Abstract][Full Text] [Related]
19. Genetic Surveillance of SARS-CoV-2 M Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764 [TBL] [Abstract][Full Text] [Related]
20. Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir. Bai F; Beringheli T; Vitaletti V; Santoro A; Molà F; Copes A; Gemignani N; Pettenuzzo S; Castoldi R; Varisco B; Nardo R; Lundgren LB; Ligresti R; Sala M; Albertini L; Augello M; Biasioli L; Bono V; Rovito R; Bini T; Passarella S; Orfeo NV; Monforte AD; Marchetti G Infect Dis Ther; 2024 Jul; 13(7):1589-1605. PubMed ID: 38829439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]